Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma

Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma

Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with previously treated advanced gastric cancer. One of the...

Full description

Bibliographic Details
Main Authors: T. A. Titova, N. S. Besova, V. A. Gorbunova, Yu. P. Kuvshinov, A. A. Filatov, A. F. Ketsba, A. A. Fedenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-07-01
Series:Медицинский совет
Subjects:
advanced gastric cancer
gastroesophageal cancer
second-line therapy
ramucirumab
paclitaxel
bleeding
Online Access:https://www.med-sovet.pro/jour/article/view/2548

Similar Items

Similar Items